CA-170

• Description :

  CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes[1][2].

• UNSPSC :

  12352005

• Target :

  PD-1/PD-L1

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/L-Threonine,_N-[[[_1S_-3-amino-1-[3-[_1R_-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]-3-oxopropyl]amino]carbonyl]-.html

• Purity :

  99.39

• Solubility :

  DMSO : 28.5 mg/mL (ultrasonic; warming)

• Smiles :

  C[C@@H](O)[C@@H](C(O)=O)NC(N[C@H](C1=NC([C@@H](N)CO)=NO1)CC(N)=O)=O

• Molecular Formula :

  C12H20N6O7

• Molecular Weight :

  360.32

• References & Citations :

  [1]Pottayil Govindan Nair Sasikumar, et al. 1,2,4-oxadiazole derivatives as immunomodulators. WO2015033299A1.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [1673534-76-3]